Amedeo Smart

Free Medical Literature Service

 

Amedeo

Breast Cancer
  Free Subscription

Articles published in
Ann Oncol
    March 2024
  1. AGOSTINETTO E, Buisseret L, Salgado R, Kok M, et al
    Residual disease post neoadjuvant chemo-immunotherapy in early triple-negative breast cancer: Does it help tailor adjuvant treatment?
    Ann Oncol. 2024 Mar 12:S0923-7534(24)00077-2. doi: 10.1016/j.annonc.2024.
    >> Share

    February 2024
  2. GENNARI A, Brain E, De Censi A, Nanni O, et al
    Early prediction of endocrine responsiveness in ER+/HER2-negative metastatic breast cancer (MBC): Pilot study with 18F-Fluoroestradiol (18F-FES) CT/PET.
    Ann Oncol. 2024 Feb 27:S0923-7534(24)00057-7. doi: 10.1016/j.annonc.2024.
    >> Share

    January 2024
  3. HARVEY-JONES E, Raghunandan M, Robbez-Masson L, Magraner-Pardo L, et al
    Longitudinal profiling identifies co-occurring BRCA1/2 reversions, TP53BP1, RIF1 and PAXIP1 mutations in PARP inhibitor resistant advanced breast cancer.
    Ann Oncol. 2024 Jan 18:S0923-7534(24)00010-3. doi: 10.1016/j.annonc.2024.
    >> Share

    December 2023
  4. SAURA C, Modi S, Krop I, Park YH, et al
    Trastuzumab Deruxtecan in Previously Treated Patients With HER2-Positive Metastatic Breast Cancer: Updated Survival Results From a Phase 2 Trial (DESTINY-Breast01).
    Ann Oncol. 2023 Dec 11:S0923-7534(23)05108-6. doi: 10.1016/j.annonc.2023.
    >> Share

  5. SPRING LM, Tolaney SM, Fell G, Bossuyt V, et al
    Response-guided neoadjuvant sacituzumab govitecan for localized triple negative breast cancer: results from the NeoSTAR trial.
    Ann Oncol. 2023 Dec 11:S0923-7534(23)05107-4. doi: 10.1016/j.annonc.2023.
    >> Share

  6. LOIBL S, Andre F, Bachelot T, Barrios CH, et al
    Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up(dagger).
    Ann Oncol. 2023 Dec 8:S0923-7534(23)05104-9. doi: 10.1016/j.annonc.2023.
    >> Share

  7. GOETZ MP, Bagegni NA, Batist G, Brufsky A, et al
    Lasofoxifene versus fulvestrant for ER+/HER2- metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial.
    Ann Oncol. 2023;34:1141-1151.
    >> Share

  8. DAMODARAN S, O'Sullivan CC, Elkhanany A, Anderson IC, et al
    Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+/HER2- breast cancer and an ESR1 mutation after disease progression on prior therapies: ELAINE 2.
    Ann Oncol. 2023;34:1131-1140.
    >> Share

  9. WANDER SA
    The ELAINE trials and the future of personalized therapy for hormone-receptor positive metastatic breast cancer.
    Ann Oncol. 2023;34:1071-1073.
    >> Share

  10. FULTON-WARD T, Middleton G
    The impact of genomic context on outcomes of solid cancer patients treated with genotype-matched targeted therapies: a comprehensive review.
    Ann Oncol. 2023;34:1113-1130.
    >> Share

    November 2023
  11. GIORDANO A, Lin NU, Tolaney SM, Mayer EL, et al
    Is there a role for continuation of CDK4/6 inhibition after progression on a prior CDK4/6 inhibitor in HR+/HER2- metastatic breast cancer?
    Ann Oncol. 2023 Nov 10:S0923-7534(23)05062-7. doi: 10.1016/j.annonc.2023.
    >> Share

  12. AGOSTINETTO E, Ignatiadis M
    ctDNA as a predictive biomarker in advanced breast cancer: Lessons from the MONALEESA studies.
    Ann Oncol. 2023;34:955-959.
    >> Share

  13. UZUNPARMAK B, Haymaker C, Raso G, Masciari S, et al
    HER2-low expression in patients with advanced or metastatic solid tumors.
    Ann Oncol. 2023;34:1035-1046.
    >> Share

    October 2023
  14. SESSA C, Paluch-Shimon S
    Reply to the Letter to the Editor 'There is no place for ovarian cancer screening in hereditary breast-ovarian cancer syndromes (in regard to "ESMO Clinical Practice Guideline on risk reduction and screening of cancer in hereditary breast-ovarian canc
    Ann Oncol. 2023 Oct 26:S0923-7534(23)04325-9. doi: 10.1016/j.annonc.2023.
    >> Share

  15. WONG NZH, Yap DWT, Ong RJM, Zhao JJ, et al
    Efficacy of Oral SERDs in the treatment of ER+, HER2 - metastatic breast cancer, a stratified analysis of the ESR1 wild type and mutant subgroups.
    Ann Oncol. 2023 Oct 21:S0923-7534(23)04328-4. doi: 10.1016/j.annonc.2023.
    >> Share

  16. THOMAS A, Shatsky R, Kalinsky K
    Moving Precision Forward: Extending Next Generation Sequencing to Operable Disease in Less Common Breast Cancer Subtypes.
    Ann Oncol. 2023 Oct 21:S0923-7534(23)04333-8. doi: 10.1016/j.annonc.2023.
    >> Share

  17. TJALMA WAA
    There is no place for ovarian cancer screening in hereditary breast-ovarian cancer syndromes.
    Ann Oncol. 2023 Oct 20:S0923-7534(23)04324-7. doi: 10.1016/j.annonc.2023.
    >> Share

    September 2023
  18. CURIGLIANO G, Burstein HJ, Gnant M, Loibl S, et al
    Understanding breast cancer complexity to improve patient outcomes: The St. Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023.
    Ann Oncol. 2023 Sep 6:S0923-7534(23)00835-9. doi: 10.1016/j.annonc.2023.
    >> Share

  19. ANDRE F, Su F, Solovieff N, Hortobagyi G, et al
    Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials.
    Ann Oncol. 2023 Sep 4:S0923-7534(23)00826-8. doi: 10.1016/j.annonc.2023.
    >> Share

    August 2023
  20. PARSONS HA, Blewett T, Chu X, Sridhar S, et al
    Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030.
    Ann Oncol. 2023 Aug 17:S0923-7534(23)00801-3. doi: 10.1016/j.annonc.2023.
    >> Share

  21. JHAVERI K, Eli LD, Wildiers H, Hurvitz SA, et al
    Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial.
    Ann Oncol. 2023 Aug 17:S0923-7534(23)00800-1. doi: 10.1016/j.annonc.2023.
    >> Share

  22. LOIBL S, Azim HA Jr, Bachelot T, Berveiller P, et al
    ESMO Expert Consensus Statements on the management of breast cancer during pregnancy (PrBC).
    Ann Oncol. 2023 Aug 9:S0923-7534(23)00798-6. doi: 10.1016/j.annonc.2023.
    >> Share

  23. OLIVIER T, Prasad V
    Costs per event averted in the neoadjuvant and adjuvant settings of early triple-negative breast cancer.
    Ann Oncol. 2023;34:723-724.
    >> Share

    July 2023
  24. TARANTINO P, Tolaney SM, Curigliano G
    Trastuzumab deruxtecan (T-DXd) in HER2-low metastatic breast cancer treatment.
    Ann Oncol. 2023 Jul 25:S0923-7534(23)00767-6. doi: 10.1016/j.annonc.2023.
    >> Share

  25. WEI T, Wang D, Yuan P
    The role of trastuzumab deruxtecan (T-DXd) in HER2-low metastatic breast cancer treatment.
    Ann Oncol. 2023 Jul 25:S0923-7534(23)00768-8. doi: 10.1016/j.annonc.2023.
    >> Share

  26. MOSELE F, Di Maio M
    Trastuzumab deruxtecan for breast cancer: do patients experience a comprehensive benefit?
    Ann Oncol. 2023;34:567-568.
    >> Share

    June 2023
  27. VILLACAMPA G, Tung NM, Pernas S, Pare L, et al
    Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer.
    Ann Oncol. 2023 Jun 9:S0923-7534(23)00721-4. doi: 10.1016/j.annonc.2023.
    >> Share

  28. TARANTINO P, Viale G, Press MF, Hu X, et al
    ESMO Expert Consensus Statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer.
    Ann Oncol. 2023 Jun 1:S0923-7534(23)00693-2. doi: 10.1016/j.annonc.2023.
    >> Share

    May 2023
  29. OLIVEIRA M, Falato C, Cejalvo JM, Vila MM, et al
    Patritumab Deruxtecan in Untreated Hormone Receptor-Positive/HER2-Negative Early Breast Cancer: Final Results from Part A of the Window-of-Opportunity SOLTI TOT-HER3 Pre-Operative Study.
    Ann Oncol. 2023 May 19:S0923-7534(23)00685-3. doi: 10.1016/j.annonc.2023.
    >> Share

  30. HARBECK N, Fasching PA, Wurstlein R, Degenhardt T, et al
    Significantly longer time to deterioration of quality of life due to CANKADO PRO-React eHealth support in HR+ HER2- metastatic breast cancer patients receiving palbociclib and endocrine therapy: Primary outcome analysis of the multicenter randomized A
    Ann Oncol. 2023 May 16:S0923-7534(23)00684-1. doi: 10.1016/j.annonc.2023.
    >> Share

  31. CURIGLIANO G, Dunton K, Rosenlund M, Janek M, et al
    Patient-reported outcomes and hospitalization data in patients with HER2-positive metastatic breast cancer receiving trastuzumab deruxtecan or trastuzumab emtansine in the phase 3 DESTINY-Breast03 study.
    Ann Oncol. 2023 May 11:S0923-7534(23)00677-4. doi: 10.1016/j.annonc.2023.
    >> Share

  32. LIPSYC-SHARF M, Tolaney SM
    Elacestrant: who are optimal candidates for the first oral SERD?
    Ann Oncol. 2023;34:449-451.
    >> Share

    April 2023
  33. GLUZ O, Kuemmel S, Nitz U, Braun M, et al
    Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamide in high-risk HR+/HER2- early breast cancer: results from the neoadjuvant part of the WSG-ADAPT-HR+/HER2- trial.
    Ann Oncol. 2023 Apr 14:S0923-7534(23)00136-9. doi: 10.1016/j.annonc.2023.
    >> Share

    March 2023
  34. KWAPISZ D, Verret B, Garcia C, Andre F, et al
    Excellent response to olaparib in metastatic HR-positive, HER2-negative breast cancer with BRIP1 mutation.
    Ann Oncol. 2023;34:315-318.
    >> Share

    January 2023
  35. LUEN SJ, Viale G, Nik-Zainal S, Savas P, et al
    Genomic characterisation of hormone receptor-positive breast cancer arising in very young women.
    Ann Oncol. 2023 Jan 25:S0923-7534(23)00047-9. doi: 10.1016/j.annonc.2023.
    >> Share

  36. REICHERT ZR, Morgan TM, Li G, Castellanos E, et al
    Prognostic value of plasma circulating tumor DNA fraction across four common cancer types: a real-world outcomes study.
    Ann Oncol. 2023;34:111-120.
    >> Share

    December 2022
  37. CURIGLIANO G, Mueller V, Borges V, Hamilton E, et al
    Corrigendum to "Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2D metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis": [Annals of Oncology 33 (2022) 3
    Ann Oncol. 2022 Dec 21:S0923-7534(22)04773-1. doi: 10.1016/j.annonc.2022.
    >> Share

  38. VAN BAELEN K, Geukens T, Maetens M, Tjan-Heijnen V, et al
    Corrigendum to "Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer": [Annals of Oncology 33 (2022) 769-785].
    Ann Oncol. 2022 Dec 16:S0923-7534(22)04746-9. doi: 10.1016/j.annonc.2022.
    >> Share

  39. LOVEDAY C, Garrett A, Law P, Hanks S, et al
    Analysis of rare disruptive germline mutations in 2135 enriched BRCA-negative breast cancers excludes additional high-impact susceptibility genes.
    Ann Oncol. 2022;33:1318-1327.
    >> Share

    November 2022
  40. TURNER NC, Swift C, Jenkins B, Kilburn L, et al
    Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate and high-risk early stage triple negative breast cancer.
    Ann Oncol. 2022 Nov 21:S0923-7534(22)04735-4. doi: 10.1016/j.annonc.2022.
    >> Share

  41. BIANCHINI G, Licata L, Viale G, Gianni L, et al
    Neoadjuvant immunotherapy in triple-negative breast cancer: lesson learnt, remaining questions.
    Ann Oncol. 2022;33:1091-1093.
    >> Share

  42. AUGUSTIN JE, Soussan P, Bass AJ
    Targeting the complexity of ERBB2 biology in gastroesophageal carcinoma.
    Ann Oncol. 2022;33:1134-1148.
    >> Share

    October 2022
  43. SESSA C, Balmana J, Bober SL, Cardoso MJ, et al
    Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline.
    Ann Oncol. 2022 Oct 19. pii: S0923-7534(22)04193.
    >> Share

  44. GEYER CE JR, Garber JE, Gelber RD, Yothers G, et al
    Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high risk, early breast cancer.
    Ann Oncol. 2022 Oct 10. pii: S0923-7534(22)04165.
    >> Share

    August 2022
  45. LOIBL S, Schneeweiss A, Huober J, Braun M, et al
    Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response.
    Ann Oncol. 2022 Aug 9. pii: S0923-7534(22)03791.
    >> Share

  46. PALUCH-SHIMON S, Cardoso F, Partridge AH, Abulkhair O, et al
    ESO-ESMO 5(th) International Consensus Guidelines for Breast Cancer in Young Women (BCY5).
    Ann Oncol. 2022 Aug 4. pii: S0923-7534(22)01858.
    >> Share

    June 2022
  47. DING K, Chen F, Priedigkeit N, Brown DD, et al
    Single cell heterogeneity and evolution of breast cancer bone metastasis and organoids reveals therapeutic targets for precision medicine.
    Ann Oncol. 2022 Jun 25. pii: S0923-7534(22)01734.
    >> Share

    May 2022
  48. VAN BAELEN K, Geukens T, Maetens M, Tjan-Heijnen V, et al
    Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer.
    Ann Oncol. 2022 May 20. pii: S0923-7534(22)01167.
    >> Share

  49. LOIBL S, Untch M, Burchardi N, Huober J, et al
    Corrigendum to "A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study": [Annals of Onco
    Ann Oncol. 2022 May 17. pii: S0923-7534(22)00676.
    >> Share

  50. MARCZYK M, Mrukwa A, Yau C, Wolf D, et al
    Treatment Efficacy Score - continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials.
    Ann Oncol. 2022 May 2. pii: S0923-7534(22)00762.
    >> Share

    April 2022
  51. TARANTINO P, Jin Q, Mittendorf EA, King TA, et al
    Clinical and pathological features of breast cancer patients eligible for adjuvant abemaciclib.
    Ann Oncol. 2022 Apr 28. pii: S0923-7534(22)00754.
    >> Share

  52. PICCART MJ, Kalinsky K, Gray R, Barlow WE, et al
    Erratum to "Gene expression signatures for tailoring adjuvant chemotherapy of luminal breast cancer: stronger evidence, greater trust": [Annals of Oncology 32 (2021) 1077-1082].
    Ann Oncol. 2022 Apr 26. pii: S0923-7534(22)00673.
    >> Share

  53. GEYER CE, Sikov WM, Loibl S
    Reply to the Letter to the Editor "Risk of MDS/AML with the addition of neoadjuvant carboplatin to standard chemotherapy for triple negative breast cancer" by A. Okines and N. Turner.
    Ann Oncol. 2022 Apr 4. pii: S0923-7534(22)00671.
    >> Share

    March 2022
  54. RUGO HS, O'Shaughnessy J, Boyle F, Toi M, et al
    Adjuvant Abemaciclib Combined with Endocrine Therapy for High Risk Early Breast Cancer: Safety and Patient-Reported Outcomes From the monarchE Study.
    Ann Oncol. 2022 Mar 22. pii: S0923-7534(22)00383.
    >> Share

  55. TOMASIK B, Bienkowski M, Jassem J
    Adding a platinum agent to neoadjuvant chemotherapy for triple-negative breast cancer: the die has not been cast.
    Ann Oncol. 2022 Mar 16. pii: S0923-7534(22)00384.
    >> Share

  56. FLEMING GF, Pagani O, Regan MM, Walley BA, et al
    Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study.
    Ann Oncol. 2022 Mar 14. pii: S0923-7534(22)00380.
    >> Share

  57. OKINES A, Turner N
    Risk of MDS/AML with the addition of neoadjuvant carboplatin to standard chemotherapy for triple negative breast cancer.
    Ann Oncol. 2022 Mar 14. pii: S0923-7534(22)00364.
    >> Share

  58. ZANELLI S, Fiorio E, Zampiva I, Zacchi F, et al
    Risk and severity of SARS-CoV-2 infection in breast cancer patients undergoing a structured infection screening program at the University and Hospital Trust of Verona.
    Ann Oncol. 2022 Mar 8. pii: S0923-7534(22)00363.
    >> Share

    February 2022
  59. GIANNI L, Huang CS, Egle D, Bermejo B, et al
    Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIP Michelangelo randomized study.
    Ann Oncol. 2022 Feb 16. pii: S0923-7534(22)00113.
    >> Share

    January 2022
  60. GEYER CE JR, Sikov WM, Huober J, Rugo HS, et al
    Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase 3 trial.
    Ann Oncol. 2022 Jan 27. pii: S0923-7534(22)00018.
    >> Share

  61. DALMARTELLO M, La Vecchia C, Bertuccio P, Boffetta P, et al
    European cancer mortality predictions for the year 2022 with focus on ovarian cancer.
    Ann Oncol. 2022 Jan 13. pii: S0923-7534(21)04881.
    >> Share

  62. GAO JJ, Krol D, Narayan P, Cardoso F, et al
    Corrigendum to "Bringing safe and effective therapies to premenopausal women with breast cancer: efforts to broaden eligibility criteria": [Annals of Oncology 32 (2021) 950-953].
    Ann Oncol. 2022 Jan 7. pii: S0923-7534(22)00002.
    >> Share

  63. NITZ UA, Gluz O, Christgen M, Grischke EM, et al
    Corrigendum to "De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12weeks of neoadjuvant dual blockade with trastuzumab and pertu
    Ann Oncol. 2022 Jan 7. pii: S0923-7534(21)04883.
    >> Share

    December 2021
  64. CURIGLIANO G, Mueller V, Borges V, Hamilton E, et al
    Tucatinib vs Placebo Added to Trastuzumab and Capecitabine for Patients with Pretreated HER2+ Metastatic Breast Cancer with and without Brain Metastases (HER2CLIMB): Final Overall Survival Analysis.
    Ann Oncol. 2021 Dec 22. pii: S0923-7534(21)04879.
    >> Share

  65. TARANTINO P, Burstein HJ, Lin NU, Krop IE, et al
    Should Ki-67 be adopted to select breast cancer patients for treatment with adjuvant abemaciclib?
    Ann Oncol. 2021 Dec 20. pii: S0923-7534(21)04877.
    >> Share

  66. SPRING L, Matikas A, Bardia A, Foukakis T, et al
    Adjuvant abemaciclib for high-risk breast cancer: the story continues.
    Ann Oncol. 2021;32:1457-1459.
    >> Share

    November 2021
  67. CARDOZO JMNL, Byng D, Drukker CA, Schmidt MK, et al
    Outcome without any adjuvant systemic treatment in stage I ER+/HER2- breast cancer patients included in the MINDACT trial.
    Ann Oncol. 2021 Nov 30. pii: S0923-7534(21)04829.
    >> Share

  68. POGGIO F, Tagliamento M, Ceppi M, Bruzzone M, et al
    Adding a platinum agent to neoadjuvant chemotherapy for triple negative breast cancer: the end of the debate.
    Ann Oncol. 2021 Nov 30. pii: S0923-7534(21)04831.
    >> Share

  69. HAN HS, Arun BK, Kaufman B, Wildiers H, et al
    Veliparib monotherapy following carboplatin/paclitaxel plus veliparib combination therapy in patients with germline BRCA-associated advanced breast cancer: results of exploratory analyses from the phase III BROCADE3 trial.
    Ann Oncol. 2021 Nov 30. pii: S0923-7534(21)04833.
    >> Share

  70. EMENS LA, Adams S, Barrios CH, Dieras V, et al
    Corrigendum to 'First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis': Annals of Oncology 2021; 32: 983-993.
    Ann Oncol. 2021 Nov 2. pii: S0923-7534(21)04520.
    >> Share

    October 2021
  71. HARBECK N, Rastogi P, Shahir A, Johnston S, et al
    Letter to the Editor for "Adjuvant Abemaciclib Combined With Endocrine Therapy for High-Risk Early Breast Cancer: Updated Efficacy and Ki-67 Analysis From the monarchE Study".
    Ann Oncol. 2021 Oct 28. pii: S0923-7534(21)04551.
    >> Share

  72. FUENTES-ANTRAS J, Cescon DW
    PARP inhibitor sensitivity in BRCA-related metastatic breast cancer: an OlympiAD later.
    Ann Oncol. 2021 Oct 19. pii: S0923-7534(21)04523.
    >> Share

  73. GENNARI A, Andre F, Barrios CH, Cortes J, et al
    ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer.
    Ann Oncol. 2021 Oct 13. pii: S0923-7534(21)04498.
    >> Share

  74. HE W, Eriksson M, Eliasson E, Grassmann F, et al
    CYP2D6 genotype predicts tamoxifen discontinuation and drug response: a secondary analysis of the KARISMA trial.
    Ann Oncol. 2021;32:1286-1293.
    >> Share

    September 2021
  75. HARBECK N, Rastogi P, Martin M, Tolaney SM, et al
    Adjuvant Abemaciclib Combined With Endocrine Therapy for High-Risk Early Breast Cancer: Updated Efficacy and Ki-67 Analysis From the monarchE Study.
    Ann Oncol. 2021 Sep 29. pii: S0923-7534(21)04494.
    >> Share

  76. WANG Y, Acs B, Robertson S, Liu B, et al
    Improved breast cancer histological grading using deep learning.
    Ann Oncol. 2021 Sep 29. pii: S0923-7534(21)04486.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016